|
1
|
Sripa B, Kaewkes S, Sithithaworn P,
Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana
S, Thinkamrop B, et al: Liver fluke induces cholangiocarcinoma.
PLoS Med. 4:e2012007. View Article : Google Scholar
|
|
2
|
Khan SA, Tavolari S and Brandi G:
Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 39
(Suppl 1):S19–S31. 2019. View Article : Google Scholar
|
|
3
|
Sripa B, Brindley PJ, Mulvenna J, Laha T,
Smout MJ, Mairiang E, Bethony JM and Loukas A: The tumorigenic
liver fluke Opisthorchis viverrini-multiple pathways to
cancer. Trends Parasitol. 28:395–407. 2012. View Article : Google Scholar
|
|
4
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View Article : Google Scholar
|
|
5
|
Ong CK, Subimerb C, Pairojkul C, Wongkham
S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, et
al: Exome sequencing of liver fluke-associated cholangiocarcinoma.
Nat Genet. 44:690–693. 2012. View Article : Google Scholar
|
|
6
|
Huang SB and Zheng CX: Gene alterations
and epigenetic changes in intrahepatic cholangiocarcinoma. Expert
Rev Anticancer Ther. 17:89–96. 2017. View Article : Google Scholar
|
|
7
|
Ahn DH, Javle M, Ahn CW, Jain A, Mikhail
S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL and Bekaii-Saab
T: Next-generation sequencing survey of biliary tract cancer
reveals the association between tumor somatic variants and
chemotherapy resistance. Cancer. 122:3657–3666. 2016. View Article : Google Scholar
|
|
8
|
Churi CR, Shroff R, Wang Y, Rashid A, Kang
HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, et al:
Mutation profiling in cholangiocarcinoma: Prognostic and
therapeutic implications. PLoS One. 9:e1153832014. View Article : Google Scholar
|
|
9
|
Liu XF, Zhang H, Zhu SG, Zhou XT, Su HL,
Xu Z and Li SJ: Correlation of p53 gene mutation and expression of
P53 protein in cholangiocarcinoma. World J Gastroenterol.
12:4706–4709. 2006. View Article : Google Scholar
|
|
10
|
Vijayakumaran R, Tan KH, Miranda PJ, Haupt
S and Haupt Y: Regulation of mutant p53 protein expression. Front
Oncol. 5:2842015. View Article : Google Scholar
|
|
11
|
Yee KS and Vousden KH: Complicating the
complexity of p53. Carcinogenesis. 26:1317–1322. 2005. View Article : Google Scholar
|
|
12
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View Article : Google Scholar
|
|
13
|
Green DR and Kroemer G: Cytoplasmic
functions of the tumour suppressor p53. Nature. 458:1127–1130.
2009. View Article : Google Scholar
|
|
14
|
Hanel W and Moll UM: Links between mutant
p53 and genomic instability. J Cell Biochem. 113:433–439. 2012.
View Article : Google Scholar
|
|
15
|
Mello SS and Attardi LD: Not all p53
gain-of-function mutants are created equal. Cell Death Differ.
20:855–857. 2013. View Article : Google Scholar
|
|
16
|
Willis A, Jung EJ, Wakefield T and Chen X:
Mutant p53 exerts a dominant negative effect by preventing
wild-type p53 from binding to the promoter of its target genes.
Oncogene. 23:2330–2338. 2004. View Article : Google Scholar
|
|
17
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar
|
|
18
|
Liu K, Ling S and Lin WC: TopBP1 mediates
mutant p53 gain of function through NF-Y and p63/p73. Mol Cell
Biol. 31:4464–4481. 2011. View Article : Google Scholar
|
|
19
|
Adorno M, Cordenonsi M, Montagner M,
Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo
V, et al: A mutant-p53/Smad complex opposes p63 to empower
TGFbeta-induced metastasis. Cell. 137:87–98. 2009. View Article : Google Scholar
|
|
20
|
Muller PA, Trinidad AG, Timpson P, Morton
JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT,
Noll JE, et al: Mutant p53 enhances MET trafficking and signalling
to drive cell scattering and invasion. Oncogene. 32:1252–1265.
2013. View Article : Google Scholar
|
|
21
|
Fontemaggi G, Dell'Orso S, Trisciuoglio D,
Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany
E, et al: The execution of the transcriptional axis mutant p53,
E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol.
16:1086–1093. 2009. View Article : Google Scholar
|
|
22
|
Blandino G, Levine AJ and Oren M: Mutant
p53 gain of function: Differential effects of different p53 mutants
on resistance of cultured cells to chemotherapy. Oncogene.
18:477–485. 1999. View Article : Google Scholar
|
|
23
|
Do PM, Varanasi L, Fan S, Li C, Kubacka I,
Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, et al:
Mutant p53 cooperates with ETS2 to promote etoposide resistance.
Genes Dev. 26:830–845. 2012. View Article : Google Scholar
|
|
24
|
Ross JS, Wang K, Gay L, Al-Rohil R, Rand
JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, et al: New
routes to targeted therapy of intrahepatic cholangiocarcinomas
revealed by next-generation sequencing. Oncologist. 19:235–242.
2014. View Article : Google Scholar
|
|
25
|
Sripa B, Leungwattanawanit S, Nitta T,
Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C and Miwa M:
Establishment and characterization of an opisthorchiasis-associated
cholangiocarcinoma cell line (KKU-100). World J Gastroenterol.
11:3392–3397. 2005. View Article : Google Scholar
|
|
26
|
Sripa B, Seubwai W, Vaeteewoottacharn K,
Sawanyawisuth K, Silsirivanit A, Kaewkong W, Muisuk K, Dana P,
Phoomak C, Lert-Itthiporn W, et al: Functional and genetic
characterization of three cell lines derived from a single tumor of
an Opisthorchis viverrini-associated cholangiocarcinoma
patient. Hum Cell. 33:695–708. 2020. View Article : Google Scholar
|
|
27
|
Sirisinha S, Tengchaisri T, Boonpucknavig
S, Prempracha N, Ratanarapee S and Pausawasdi A: Establishment and
characterization of a cholangiocarcinoma cell line from a Thai
patient with intrahepatic bile duct cancer. Asian Pac J Allergy
Immunol. 9:153–157. 1991.
|
|
28
|
Netto C, Thomaz-Soccol V, Sepúlveda L,
Oliveira Garcia G and Timenetsky J: Quality control of
biotechnological inputs detecting mycoplasma. Braz Arch Biol Techn.
58:239–243. 2015. View Article : Google Scholar
|
|
29
|
Hansson MD, Rzeznicka K, Rosenback M,
Hansson M and Sirijovski N: PCR-mediated deletion of plasmid DNA.
Anal Biochem. 375:373–375. 2008. View Article : Google Scholar
|
|
30
|
Matlashewski GJ, Tuck S, Pim D, Lamb P,
Schneider J and Crawford LV: Primary structure polymorphism at
amino acid residue 72 of human p53. Mol Cell Biol. 7:961–963. 1987.
View Article : Google Scholar
|
|
31
|
Phimsen S, Kuwahara K, Nakaya T, Ohta K,
Suda T, Rezano A, Kitabatake M, Vaeteewoottacharn K, Okada S, Tone
S and Sakaguchi N: Selective cell death of p53-insufficient cancer
cells is induced by knockdown of the mRNA export molecule GANP.
Apoptosis. 17:679–690. 2012. View Article : Google Scholar
|
|
32
|
Freed-Pastor WA and Prives C: Mutant p53:
One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar
|
|
33
|
Lim YP, Lim TT, Chan YL, Song AC, Yeo BH,
Vojtesek B, Coomber D, Rajagopal G and Lane D: The p53
knowledgebase: An integrated information resource for p53 research.
Oncogene. 26:1517–1521. 2007. View Article : Google Scholar
|
|
34
|
Weissmueller S, Manchado E, Saborowski M,
Morris JP IV, Wagenblast E, Davis CA, Moon SH, Pfister NT,
Tschaharganeh DF, Kitzing T, et al: Mutant p53 drives pancreatic
cancer metastasis through cell-autonomous PDGF receptor β
signaling. Cell. 157:382–394. 2014. View Article : Google Scholar
|
|
35
|
Vogiatzi F, Brandt DT, Schneikert J, Fuchs
J, Grikscheit K, Wanzel M, Pavlakis E, Charles JP, Timofeev O, Nist
A, et al: Mutant p53 promotes tumor progression and metastasis by
the endoplasmic reticulum UDPase ENTPD5. Proc Natl Acad Sci USA.
113:E8433–E8442. 2016. View Article : Google Scholar
|
|
36
|
Schmitz AA, Govek EE, Bottner B and Van
Aelst L: Rho GTPases: Signaling, migration, and invasion. Exp Cell
Res. 261:1–12. 2000. View Article : Google Scholar
|
|
37
|
Yue X, Zhang C, Zhao Y, Liu J, Lin AW, Tan
VM, Drake JM, Liu L, Boateng MN, Li J, et al: Gain-of-function
mutant p53 activates small GTPase Rac1 through SUMOylation to
promote tumor progression. Genes Dev. 31:1641–1654. 2017.
View Article : Google Scholar
|
|
38
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar
|
|
39
|
Muller PA, Caswell PT, Doyle B, Iwanicki
MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL,
Gosselin P, et al: Mutant p53 drives invasion by promoting integrin
recycling. Cell. 139:1327–1341. 2009. View Article : Google Scholar
|
|
40
|
Ahn JH, Kim TJ, Lee JH and Choi JH: Mutant
p53 stimulates cell invasion through an interaction with Rad21 in
human ovarian cancer cells. Sci Rep. 7:90762017. View Article : Google Scholar
|
|
41
|
Mantovani F, Walerych D and Sal GD:
Targeting mutant p53 in cancer: A long road to precision therapy.
FEBS J. 284:837–850. 2017. View Article : Google Scholar
|
|
42
|
Treekitkarnmongkol W and Suthiphongchai T:
High expression of ErbB2 contributes to cholangiocarcinoma cell
invasion and proliferation through AKT/p70S6K. World J
Gastroenterol. 16:4047–4054. 2010. View Article : Google Scholar
|
|
43
|
Runnebaum IB, Nagarajan M, Bowman M, Soto
D and Sukumar S: Mutations in p53 as potential molecular markers
for human breast cancer. Proc Natl Acad Sci USA. 88:10657–10661.
1991. View Article : Google Scholar
|
|
44
|
Bertheau P, Turpin E, Rickman DS, Espie M,
de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de
Roquancourt A, et al: Exquisite sensitivity of TP53 mutant and
basal breast cancers to a dose-dense epirubicin-cyclophosphamide
regimen. PLoS Med. 4:e902007. View Article : Google Scholar
|
|
45
|
Link DC, Schuettpelz LG, Shen D, Wang J,
Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le
Beau M, et al: Identification of a novel TP53 cancer susceptibility
mutation through whole-genome sequencing of a patient with
therapy-related AML. JAMA. 305:1568–1576. 2011. View Article : Google Scholar
|
|
46
|
Khoury MP and Bourdon JC: The isoforms of
the p53 protein. Cold Spring Harb Perspect Biol. 2:a0009272010.
View Article : Google Scholar
|
|
47
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar
|
|
48
|
Chen J: The cell-cycle arrest and
apoptotic functions of p53 in tumor initiation and progression.
Cold Spring Harb Perspect Med. 6:a0261042016. View Article : Google Scholar
|
|
49
|
Wu SJ, Lin CT, Agathangelidis A, Lin LI,
Kuo YY, Tien HF and Ghia P: Distinct molecular genetics of chronic
lymphocytic leukemia in Taiwan: Clinical and pathogenetic
implications. Haematologica. 102:1085–1090. 2017. View Article : Google Scholar
|
|
50
|
Kishimoto Y, Murakami Y, Shiraishi M,
Hayashi K and Sekiya T: Aberrations of the p53 tumor suppressor
gene in human non-small cell carcinomas of the lung. Cancer Res.
52:4799–4804. 1992.
|
|
51
|
Yamada H, Shinmura K, Okudela K, Goto M,
Suzuki M, Kuriki K, Tsuneyoshi T and Sugimura H: Identification and
characterization of a novel germ line p53 mutation in familial
gastric cancer in the Japanese population. Carcinogenesis.
28:2013–2018. 2007. View Article : Google Scholar
|
|
52
|
Lal-Nag M and Morin PJ: The claudins.
Genome Biol. 10:2352009. View Article : Google Scholar
|
|
53
|
Ding L, Lu Z, Lu Q and Chen YH: The
claudin family of proteins in human malignancy: A clinical
perspective. Cancer Manag Res. 5:367–375. 2013.
|
|
54
|
Kramer F, White K, Kubbies M, Swisshelm K
and Weber BH: Genomic organization of claudin-1 and its assessment
in hereditary and sporadic breast cancer. Hum Genet. 107:249–256.
2000. View Article : Google Scholar
|
|
55
|
Resnick MB, Konkin T, Routhier J, Sabo E
and Pricolo VE: Claudin-1 is a strong prognostic indicator in stage
II colonic cancer: A tissue microarray study. Mod Pathol.
18:511–518. 2005. View Article : Google Scholar
|
|
56
|
Chao YC, Pan SH, Yang SC, Yu SL, Che TF,
Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, et al: Claudin-1 is a
metastasis suppressor and correlates with clinical outcome in lung
adenocarcinoma. Am J Respir Crit Care Med. 179:123–133. 2009.
View Article : Google Scholar
|
|
57
|
Higashi Y, Suzuki S, Sakaguchi T, Nakamura
T, Baba S, Reinecker HC, Nakamura S and Konno H: Loss of claudin-1
expression correlates with malignancy of hepatocellular carcinoma.
J Surg Res. 139:68–76. 2007. View Article : Google Scholar
|
|
58
|
Suren D, Yildirim M, Kaya V, Alikanoglu
AS, Bulbuller N, Yildiz M and Sezer C: Loss of tight junction
proteins (Claudin 1, 4, and 7) correlates with aggressive behavior
in colorectal carcinoma. Med Sci Monit. 20:1255–1262. 2014.
View Article : Google Scholar
|
|
59
|
Hall A: Rho GTPases and the actin
cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar
|
|
60
|
Schmidt A and Hall A: Guanine nucleotide
exchange factors for Rho GTPases: Turning on the switch. Genes Dev.
16:1587–1609. 2002. View Article : Google Scholar
|
|
61
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar
|
|
62
|
DeMali KA and Burridge K: Coupling
membrane protrusion and cell adhesion. J Cell Sci. 116:2389–2397.
2003. View Article : Google Scholar
|
